Live·Verified funding discovery · 2026.2

882 grants · 20 open · 435 companies · 2640 concepts882 / 20 / 435 / 2640

⧗GRANTDocumentary Production · Screen Australia closes 24 SEPT⧗GRANTInstitutional Development Award (IDeA) for Clinical & Translational Research · National Institute of General Medical Sciences (NIGMS), National Institutes of Health closes 25 SEPT△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE882 grants in catalogue · 20 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA⧗GRANTDocumentary Production · Screen Australia closes 24 SEPT⧗GRANTInstitutional Development Award (IDeA) for Clinical & Translational Research · National Institute of General Medical Sciences (NIGMS), National Institutes of Health closes 25 SEPT△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE882 grants in catalogue · 20 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA

← Back to Eternal Search

Erik Musalem

individual

Fund operatorEcosystem influencer

About

Erik Musalem is Founder & Managing Partner of Sila B Health Ventures, a boutique VC firm deploying $5M–$20M micro-funds into pre-seed and early-stage biotech. Previously a Fortune 500 executive as Country Managing Director at Boehringer Ingelheim (Philippines) and at Gilead Sciences Mexico. He also runs Evolve & Grow, advising founder-led companies on CEO evolution and enterprise value growth, and serves as CEO Forum Chair and Stanford Seed Consultant.

Areas of interest

biotechAI in pharmalongevityhealthtechearly-stage venturepharma operationsCEO developmentemerging fund managersfamily office LP development